FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891089991> ?p ?o ?g. }

• W2891089991 abstract "Seven years ago a chronic lymphocytic leukemia patient was for the first time successfully treated with chimeric antigen receptor (CAR)-modified T cells (CAR-T cells) to target CD19 overexpression in tumor cells. This was the beginning of the development of a new type of immunotherapy treatment in cancer patients. Since then, identification of novel antigens expressed in tumor cells and optimization of both CAR constructs and protocols of administration have opened up new avenues for the successful treatment of other hematological malignancies. However, research still continues to avoid some problems such as toxicities associated with the treatment and to find strategies to avoid tumor cell immune evasion mechanisms. On the other hand, for solid tumors, CAR-T therapy results are still in an early phase. In contrast to hematological malignancies, the complex tumor heterogeneity of solid tumors has led to the research of novel and challenging strategies to improve CAR-T cell activity. Here, we will review the main clinical results obtained with CAR-T cells in hematological malignancies, specifically focusing on CAR-T-19 and CAR-T against B-cell maturation antigen (CAR-T-BCMA). Moreover, we will mention the main problems that decrease CAR-T cell activity in solid tumors and the strategies to overcome them. Finally, we will present some of the first clinical results obtained for solid tumors.Yedi sene önce kronik lenfositik lösemili bir hasta ilk kez başarılı olarak tümör hücrelerinde aşırı sunulan CD19’u hedefleyen kimerik antijen reseptör (CAR)-ile değiştirilmiş T hücreleri (CAR-T hücreleri) ile tedavi edilmiştir. Bu kanser hastalarında yeni bir tip immünoterapinin gelişiminin başlangıcını oluşturmaktaydı. Bunu takiben, tümör hücrelerinde sunulan yeni antijenlerin tanımlanması ve CAR yapılarını ve uygulama protokolleri diğer hematolojik habis tümörlerin başarılı tedavisi için yeni yollar açmıştır. Ancak, tedavi ile ilişkili toksisite gibi bazı problemlerin önlenmesi ve tümör hücresinin immün kaçış mekanizmalarıyla baş edilmesi ile ilgili çalışmalar halen devam etmektedir. Ayrıca, solid tümörler için, CAR-T tedavi sonuçları halen erken dönemdedir. Hematolojik habis tümörlerin aksine, solid tümörlerin karmaşık tümör heterojenitesi CAR-T hücre aktivitesi arttırmaya yönelik yeni ve zorlayıcı stratejilerinin araştırılmasına yol açmıştır. Burada, CAR-T hücrelerinin hematolojik habis tümörlerdeki, özellikle de CAR-T-19 ve B-hücre matürasyon antijenine karşı CAR-T’nin (CAR-T-BCMA) başlıca klinik sonuçlarını gözden geçireceğiz. Ayrıca, solid tümörlerde CAR-T hücre aktivitesini azaltan problemlerden ve bunların üstesinden gelmeye yarayan stratejilerden bahsedeceğiz. Son olarak, solid tümörlerdeki ilk klinik çalışmaların bazılarını sunacağız." @default.
• W2891089991 created "2018-09-27" @default.
• W2891089991 creator A5009241756 @default.
• W2891089991 creator A5012535366 @default.
• W2891089991 creator A5063848310 @default.
• W2891089991 creator A5068807291 @default.
• W2891089991 creator A5079200899 @default.
• W2891089991 date "2018-09-06" @default.
• W2891089991 modified "2023-10-18" @default.
• W2891089991 title "CAR-T cell therapy, a door is open to find innumerable possibilities of treatments for cancer patients" @default.
• W2891089991 cites W1619537825 @default.
• W2891089991 cites W1828443506 @default.
• W2891089991 cites W1868169777 @default.
• W2891089991 cites W1984287161 @default.
• W2891089991 cites W1985579610 @default.
• W2891089991 cites W1991890073 @default.
• W2891089991 cites W1999843922 @default.
• W2891089991 cites W2001327683 @default.
• W2891089991 cites W2014751400 @default.
• W2891089991 cites W2019629676 @default.
• W2891089991 cites W2042755939 @default.
• W2891089991 cites W2051549641 @default.
• W2891089991 cites W2068173904 @default.
• W2891089991 cites W2076991609 @default.
• W2891089991 cites W2077994554 @default.
• W2891089991 cites W2082515801 @default.
• W2891089991 cites W2082708772 @default.
• W2891089991 cites W2087055812 @default.
• W2891089991 cites W2092475062 @default.
• W2891089991 cites W2092692114 @default.
• W2891089991 cites W2093065396 @default.
• W2891089991 cites W2094945699 @default.
• W2891089991 cites W2097175022 @default.
• W2891089991 cites W2105400883 @default.
• W2891089991 cites W2105879190 @default.
• W2891089991 cites W2107806760 @default.
• W2891089991 cites W2112359076 @default.
• W2891089991 cites W2122459559 @default.
• W2891089991 cites W2124513722 @default.
• W2891089991 cites W2130011407 @default.
• W2891089991 cites W2130338247 @default.
• W2891089991 cites W2133298966 @default.
• W2891089991 cites W2153147430 @default.
• W2891089991 cites W2166487857 @default.
• W2891089991 cites W2169579205 @default.
• W2891089991 cites W2184270030 @default.
• W2891089991 cites W2316953565 @default.
• W2891089991 cites W2324071661 @default.
• W2891089991 cites W2471662063 @default.
• W2891089991 cites W2504729294 @default.
• W2891089991 cites W2513177163 @default.
• W2891089991 cites W2566677727 @default.
• W2891089991 cites W2567424265 @default.
• W2891089991 cites W2587691649 @default.
• W2891089991 cites W2592882744 @default.
• W2891089991 cites W2595477151 @default.
• W2891089991 cites W2605626471 @default.
• W2891089991 cites W2606325744 @default.
• W2891089991 cites W2606925453 @default.
• W2891089991 cites W2735691291 @default.
• W2891089991 cites W2738678436 @default.
• W2891089991 cites W2740938625 @default.
• W2891089991 cites W2743083943 @default.
• W2891089991 cites W2754562068 @default.
• W2891089991 cites W2767250204 @default.
• W2891089991 cites W2773804840 @default.
• W2891089991 cites W2775369717 @default.
• W2891089991 cites W2775982617 @default.
• W2891089991 cites W2787301955 @default.
• W2891089991 cites W2787621143 @default.
• W2891089991 cites W2790173378 @default.
• W2891089991 cites W2790865199 @default.
• W2891089991 cites W2793787928 @default.
• W2891089991 cites W2795019304 @default.
• W2891089991 doi "https://doi.org/10.4274/tjh.2018.0196" @default.
• W2891089991 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6256819" @default.
• W2891089991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30185400" @default.
• W2891089991 hasPublicationYear "2018" @default.
• W2891089991 type Work @default.
• W2891089991 sameAs 2891089991 @default.
• W2891089991 citedByCount "6" @default.
• W2891089991 countsByYear W28910899912020 @default.
• W2891089991 countsByYear W28910899912021 @default.
• W2891089991 countsByYear W28910899912022 @default.
• W2891089991 crossrefType "journal-article" @default.
• W2891089991 hasAuthorship W2891089991A5009241756 @default.
• W2891089991 hasAuthorship W2891089991A5012535366 @default.
• W2891089991 hasAuthorship W2891089991A5063848310 @default.
• W2891089991 hasAuthorship W2891089991A5068807291 @default.
• W2891089991 hasAuthorship W2891089991A5079200899 @default.
• W2891089991 hasBestOaLocation W28910899911 @default.
• W2891089991 hasConcept C121608353 @default.
• W2891089991 hasConcept C126322002 @default.
• W2891089991 hasConcept C147483822 @default.
• W2891089991 hasConcept C203014093 @default.
• W2891089991 hasConcept C2776090121 @default.
• W2891089991 hasConcept C2777701055 @default.
• W2891089991 hasConcept C2777938653 @default.
• W2891089991 hasConcept C2778461978 @default.
• W2891089991 hasConcept C2778957590 @default.

• next